

Acknowledgement

This presentation was prepared for the South Southwest Prevention Technology Transfer Center (PTTC) Network under a cooperative agreement from the Substance Abuse and Mental Health Services Administration (SAMHSA). All material appearing in this publication, except that taken directly from copyrighted sources, is in the public domain and may be reproduced or copied without permission from SAMHSA or the authors. Citation of the source is appreciated. Do not reproduce or distribute this publication for a fee without specific, written authorization from the South Southwest Prevention Technology Transfer Center. For more information on obtaining copies of this publication, contact us at pttc6@ou.edu.

At the time of this publication, Miriam E. Delphin-Rittmon, Ph.D, served as Assistant Secretary for Mental Health and Substance Use in the U.S. Department of Health and Human Services and the Administrator of the Substance Abuse and Mental Health Services Administration.

The opinions expressed herein are the view of PTTC Network and do not reflect the official position of the Department of Health and Human Services (DHHS), SAMHSA. No official support or endorsement of DHHS, SAMHSA, for the opinions described in this document is intended or should be inferred.

This work is supported by grants 6UR1TI08205-02M002, SM081726 and 1H79SP081006-01 from the Department of Health and Human Services, Substance Abuse and Mental Health Services Administration.






Facilitator



Fernando Montero, Ph.D.

South Southwest PTTC Associate



Roadmap for Today

- Overview of the Issue
- ✓ Impact of Xylazine
- ✓ Harm Reduction
- ✓ The Role of Prevention
- ✓ Summary
- Evaluation



Learning Objectives




Summarize how the sudden expansion of xylazine, fentanyl, and crystal methamphetamine use is related to the history of U.S. drug markets since 1990.



Describe how each of these substances relate to one another in consumption and public health impact, including drug overdose risk.



Examine avenues for public health interventions.



Poll Question

Is Xylazine an Opioid?

- 1. Yes
- 2. No
- 3. Not sure

Xylazine: Overview and Pharmacology

- Xylazine is an alpha-2 adrenergic agonist that has long been used by veterinarians to treat large animals such as horses and cattle.
- It is not an opioid
- It is a synthetic sedative







Xylazine: Effects on Humans

- Deep sedation and heavy nod within 20/30 minutes
- Slowing down the central nervous system
- Slow breathing
- Low blood pressure
- Slow heart rate
- High/Low blood sugar
- Amnesia
- Severe skin ulcers and abscesses





Xylazine-Related Skin Wounds

WARNING:

The following slide contains graphic depictions of xylazine-related skin wounds



Xylazine-Related Skin Wounds







How is Xylazine Administered?





Poll Question

Which of the following effects are not related to Xylazine use by humans?

- 1. Slowed Breathing
- 2. Low Blood Pressure
- 3. Diarrhea
- 4. Open wounds



What do you know about the prevalence of xylazine in your community?

Recent History of U.S. Street Opioid Supply

1991-2013

- Mexican black tar heroin west of Mississippi River
- Colombian powder heroin east of the Mississippi
- Mixed supply in Midwestern cities like Chicago (Ciccarone & Bourgois 2003)

2013-2019

 Mexican powder heroin displaces Colombian heroin from East Coast markets and fentanyl enters opioid supply chains primarily on the East Coast (Ciccarone 2021)

2017

Xylazine becomes increasingly prevalent in Rustbelt region, beginning in (Friedman, Montero, Bourgois et al. 2022), as fentanyl begins to spread west (Shover et al. 2020)

2020-present

- Opioid supply on East Coast increasingly becomes a mix of fentanyl and xylazine ("tranq") as heroin disappears.
- Mexican methamphetamine enters East Coast/Rust Belt street markets formerly dominated by heroin and cocaine.
- The West Coast opioid market becomes a predominantly pill-oriented market where people who use drugs crush and smoke fentanyl pills often advertised as Oxycodone or Percocets (Montero et al. 2022).

Fentanyl's Uneven Spread

Fentanyl's spread has been conditioned by preexisting geographic distribution of heroin formulations (powder vs. black tar)

Fentanyl prevalence on West Coast is increasing substantially but is still below East Coast/Midwest levels (Shover et al. 2020)

Most of the fentanyl entering the country now crosses Southwestern border points with purity levels around 1.5 - 10% (DEA PFD 2020:8)





Fentanyl Beyond "Potency"

- Experience of fentanyl consumption (vs. heroin)
 - Duration of effect / withdrawal symptoms / frequency of injection
 - Quality of "high" (Montero et al. 2022; Ciccarone, Ondocsin, and Mars 2017)
 - Fentanyl shapes later changes as its deficiencies open space for new additives and substances (xylazine, meth)

Xylazine

- In 10 jurisdictions—representing all 4 US Census Regions—xylazine is increasingly implicated in overdose mortality, rising from 0.36% of deaths in 2015 to 6.7% in 2020.
- In 2020, the highest xylazine prevalence was observed in Philadelphia (34.7% of overdose deaths), followed by Maryland (19.2%) and Connecticut (10.2%)
- In Philadelphia in 2020, fentanyl was present in 98.4% of xylazineinvolved-overdose deaths



Xylazine

Most recent drug testing data in Philadelphia shows relative concentration of xylazine and fentanyl in local "dope" supply

Average "dope" sample consists of 2-10% fentanyl, 30-40% xylazine, and no heroin (CSFRE 2022)



Number of Overdoses by Region

Region	2020	2021	Percent Increase
Northeast	631	1,281	103%
South	116	1,423	1,127%
Midwest	57	351	516%
West	4	34	750%

Source: DEA 2023

Why Xylazine? Why Now?

Tom, male, white, unhoused 35-year-old opioid and meth injector in Philadelphia:

"Fentanyl is such a short-lived high, that the high... It's a good high but it's so short that the nod is over real quick and you get sicker faster. See, the tranq extends the high, it gives the dope more of a heroin effect, it's a good rush with the heroin-like 'legs' [duration of high].

"But they straight put bags out there that are just all tranq. You shoot it, you feel no rush. Tranq-fent is like you shoot it; you get the rush of the fentanyl; then the tranquilizer comes in; you nod; and you fall asleep. A straight tranq bag is like, you shoot it; you get no rush; you're sitting there for a second talking; and then you're waking up 2-3 hours later in a weird position. Like one case, I lit a Newport [menthol cigarette]; I shot a bag with a Newport; I woke up with a hole of Newport burnt into my stomach [showing the scar, laughing]. You could literally drown in a half-inch of water if you did a tranq bag and you fell out."

Source: Montero et al. 2022



Why Xylazine? Why Now?

- Limits of fentanyl adulteration
 - Length and quality of "high"
 - Fentanyl cannot serve as diluent or bulk of substance sold as "dope"
- Xylazine compensates for deficiencies introduced by fentanyl

Which Region of the US has seen the highest number of Xylazine-Positive Overdose Deaths?

- 1. South
- 2. Northeast
- 3. Midwest
- 4. West





Xylazine has introduced new problems:

- It is not an opioid (there is a need for new overdose reversal agents to complement, not replace, naloxone)
- Ulcers/extensive skin wounds
- Risk of sexual assault and muggings
- Not just overdose; withdrawal and detox

Xylazine-Involved Suspected Overdoses

Recovery position, airway maneuvers to clear airway

Pulse oximetry, airway monitoring, supplemental oxygen as needed

No known antidote

Naloxone administration recommended if uncertain cause of overdose

Try to move the patient semi-regularly if in deep xylazine nod – prevent rhabdomyolysis





Methamphetamine

- "Fentanyl is so short-lived that we gotta get high every 6 hours. But sometimes, let's say things were tough or whatever, if we were 10 hours in and you started getting sick, a nice shot of meth will hold you over for another 6 hours, as far as not being sick altogether. You just wouldn't be as sick, I mean eventually it would turn against you but it would keep you feeling better to get up and make a move to make money."
- "Meth does its part too, because if you really don't have the money, meth can keep you well for a little bit longer, it kind of will help you like, give you some time to gather up money to find some dope, you know what I mean? And you can stay up later, scheming to get money, or if you do your thing at night, boosting or whatever. I scrap, so a lot of my work is nighttime stuff."

The Increasingly Synthetic Polydrug Context

- Impact on HIV and hepatitis C risk: an era of countervailing forces
 - Xylazine vs. methamphetamine
 - Psychostimulant overdose deaths in the US rose by 625% between 2012 and 2019 (Hedegaard, Minino & Warner 2020:4)
 - Plenty of room for expansion east of the Mississippi River:
 CDC reports that age-adjusted death rates for drug overdoses involving psychostimulants ranged from 1.2 [per 100,000] in the Northeast to 5.3 in the West (CDC 2019:37)

What is the street name for Xylazine?

- 1. Tranq
- 2. Tranq Dope
- 3. Zombie Drug
- 4. Sleep-Cut
- 5. All of the above



Looking Ahead

- Overdose prevention centers will prevent both overdoses and sexual assault
- Support for community-based gas chromatography-mass spectrometry testing in addition to fentanyl test strips (FTS) and xylazine test strips (XTS)
- Safe Supply

Toward Supply-Side Harm Reduction

- Importance of not vilifying people who sell drugs (street sellers)
- It is crucial to understand socioeconomic organization of narcotics markets at all levels of supply chain (vs. simply drug use)
- Enhances understanding of how supply changes happen and how public health can intervene more efficiently and non-punitively





Prevention and Treatment Opportunities

Continue focusing on core prevention strategies, but beyond that you can:

- Increase and improve data collection
- Pilot new evidence based programs/adapt existing programs and publish the results
- Continue to build cultural humility and culturally responsive practices

Other Potential Strategies for Prevention

- Advocate for greater access to treatment/detox
- Raise awareness and increase information about xylazine
- Draw from lessons-learned about fentanyl messaging campaigns



What are some steps that you're taking to address xylazine use?

Or that you will take if xylazine becomes an issue in your community?



Summary

- Xylazine use is a growing issue across the United States
- Prevalence is likely still relatively low, outside of certain localities
- It is Important for prevention and public health to prepare and act before trends worsen
- Cultural humility and other best practices learned throughout the course of the opioid epidemic can help



Let's hear from you! What are your questions?



For further questions, contact:

Derrick Newby, T/TA Specialist South Southwest PTTC Region 6

Connect with us @



SSW PTTC website



Join our mailing list



Products and resources

References

1. Cai, Y, Dai, Z, Wen, S and Bhandari, R. 2020. Risk factors associated with infection of blood-borne virus among people who used methamphetamine. BMC Infectious Diseases, 20:742. DOI: https://doi.org/10.1186/s12879-020-05464-y

2. Centers for Disease Control and Prevention, US (CDC). 2019. 2019 Annual Surveillance Report of Drug-Related Risks and Outcomes. Centers for Disease Control and Prevention, U.S. Department

of Health and Human Services.

3. Center for Forensic Science Research and Education (CFSRE). 2022. Drug checking – Q2 2022: Philadelphia, Pennsylvania. USA. [online access at https://www.cfsre.org/images/content/reports/drug_checking/2022-Q2_Drug-Checking Report_Philadelphia.pdf

Ciccarone, D. 2021. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. *Current Opinion in Psychiatry*, 34(4): 344-350.
 Ciccarone, D. and Bourgois, P. 2003. Explaining the geographic variation of HIV among Injection Drug Users in the United States. *Substance Use & Misuse*, 38(14): 2049-2063.
 Ciccarone, D., Ondocsin, J. and Mars, S. 2017. Heroin uncertainties: Exploring users' perceptions of fentanyl-adulterated and -substituted 'heroin'. *International Journal of Drug Policy* 46: 146-155.
 Drug Enforcement Administration Philadelphia Field Division (DEA PFD). 2020. *Illicit Stimulant Availability in Poppeylyania*, 2020.

Availability in Pennsylvania, 2020.
8. Friedman, J., Montero, F., Bourgois, P., Wahbi, R., Dye, D., Goodman, D., and Shover, C. 2022. Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis. *Drug and Alcohol Dependence*, 233: 109380. https://doi.org/10.1016/j.drugalcdep.2022.109380



References

9. Hedegaard, H., Minino, A. and Warner, M. 2020. Drug overdose deaths in the United States, 1999-2019. NCHS Data Brief, 394. Hyattsville, MD: National Center for Health Statistics.

10. Love, JS., Levine, M., Aldy, K., Brent, J., Krotulski, AJ., Logan, BK., Vargas-Torres, C., Walton, SE., Amaducci, A., Calello, D., et al. Opioid Overdoses Involving Xylazine in Emergency Department

Patients: A Multicenter Study. Clinical Toxicology 61(3):173-180.

11. Montero, F., Bourgois, P., and Friedman, J. Potency-Énhancing Synthetics in the Drug Overdose Epidemic: Xylazine ("Tranq"), Fentanyl, Methamphetamine, and the Displacement of Heroin in Philadelphia and Tijuana. Journal of Illicit Economies and Development 4(2):204-222. https://iied.lse.ac.uk/articles/10.31389/jied.122

12. Reed, MK., Imperato, NS., Bowles, JM., Salcedo, VJ., Guth, A., Rising, KL. 2022. Perspectives of People in Philadelphia Who Use Fentanyl/Heroin Adulterated with the Animal Tranquilizer Xylazine: Making a Case for Xylazine Test Strips. Drug and Alcohol Reports 4 100074.

DOI: https://doi.org/10.1016/j.dadr.2022.100074

13. Reyes, JC., Negron, JL., Colon, HM., Padilla, AM., Millan, MY., Matos, TD., and Robles, RR. 2012. The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico. Journal of Urban Health: Bulletin of the New York Academy of Medicine, 89(3): 519-526.

14. Rodriguez, N., Vargas Vidot, J., Panelli, J., Colon, H., Ritchie, B., and Yamamura, Y. 2008. GC-MS confirmation of xylazine (Rompun), a veterinary sedative, in exchanged needles. Drug and Alcohol Dependence, 96: 290-293.

References

- 15. Shearer, RD., Howell, BA., Bart, G., Winkelman, TNA. 2020. Substance Use Patterns and Health Profiles among US Adults Who Use Opioids, Methamphetamine, or Both, 2015-2018. Drug and Alcohol Dependence 214(1):108162.
- 16. Shover, CL., Falasinnu, TO., Dwyer, CL., Benitez Santos, N., Cunningham, NJ., Freedman, RB., Vest, NA. and Humphreys, K. 2020. Steep increases in fentanyl-related mortality west of the Mississippi River: Recent evidence from county and state surveillance. Drug and Alcohol Dependence 216: 1-8.
- 17. Torruella, RA. 2011. Xylazine (veterinary sedative) use in Puerto Rico. Substance Abuse Treatment, Prevention, and Policy 6(7): 1-4.
 - https://substanceabusepolicy.biomedcentral.com/articles/10.1186/1747-597X-6-7